Kim So-Jung, Jung Ji-Won, Ha Hye-Yeong, Koo Soo Kyung, Kim Eung-Gook, Kim Jung-Hyun
Division of Intractable Diseases, Center for Biomedical Sciences, National Institute of Health and Korea Centers for Diseases Control and Prevention, Cheongju, Korea.; Department of Biochemistry, College of Medicine, Chungbuk National University, Cheongju, Korea.
Division of Intractable Diseases, Center for Biomedical Sciences, National Institute of Health and Korea Centers for Diseases Control and Prevention, Cheongju, Korea.
Blood Res. 2017 Mar;52(1):37-43. doi: 10.5045/br.2017.52.1.37. Epub 2017 Mar 27.
Embryonic stem cells (ESCs) can be expanded infinitely and have the potential to differentiate into hematopoietic stem cells (HSCs); thus, they are considered a useful source of cells for HSC production. Although several technical methods for engineering HSCs from pluripotent stem cells have been developed, clinical application of HSCs engineered from pluripotent stem cells is restricted because of the possibility of xenogeneic contamination resulting from the use of murine materials.
Human ESCs (CHA-hES15) were cultured on growth factor-reduced Matrigel-coated dishes in the mTeSR1 serum-free medium. When the cells were 70% confluent, we initiated HSC differentiation by three methods involving (1) knockout serum replacement (KSR), cytokines, TGFb1, EPO, and FLT3L; (2) KSR, cytokines, and bFGF; or (3) cytokines and bFGF.
Among the three differentiation methods, the minimal number of cytokines without KSR resulted in the greatest production of HSCs. The optimized method resulted in a higher proportion of CD34CD43 hematopoietic progenitor cells (HPCs) and CD34CD45 HPCs compared to the other methods. In addition, the HSCs showed the potential to differentiate into multiple lineages of hematopoietic cells .
In this study, we optimized a two-step, serum-free, animal protein-free, KSR-free, feeder-free, chemically defined monolayer culture method for generation of HSCs and hematopoietic stem and progenitor cells (HSPCs) from human ESCs.
胚胎干细胞(ESCs)能够无限扩增,并且具有分化为造血干细胞(HSCs)的潜力;因此,它们被认为是用于生产造血干细胞的有用细胞来源。尽管已经开发了几种从多能干细胞工程化制造造血干细胞的技术方法,但由于使用鼠源材料可能导致异种污染,多能干细胞工程化制造的造血干细胞的临床应用受到限制。
人胚胎干细胞(CHA-hES15)在生长因子减少的基质胶包被培养皿上于mTeSR1无血清培养基中培养。当细胞达到70%汇合度时,我们通过三种方法启动造血干细胞分化,包括(1)敲除血清替代物(KSR)、细胞因子、转化生长因子β1(TGFβ1)、促红细胞生成素(EPO)和FMS样酪氨酸激酶3配体(FLT3L);(2)KSR、细胞因子和碱性成纤维细胞生长因子(bFGF);或(3)细胞因子和bFGF。
在这三种分化方法中,不使用KSR的最少细胞因子数量导致了最大量的造血干细胞产生。与其他方法相比,优化后的方法产生的CD34+CD43+造血祖细胞(HPCs)和CD34+CD45+ HPCs比例更高。此外,造血干细胞显示出分化为多种造血细胞谱系的潜力。
在本研究中,我们优化了一种两步法、无血清、无动物蛋白、无KSR、无饲养层、化学成分明确的单层培养方法,用于从人胚胎干细胞生成造血干细胞和造血干祖细胞(HSPCs)。